NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds investors who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE:PRGO) securities to contact NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds investors who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE:PRGO) securities to contact

PRGO: Kirby McInerney LLP Advises Perrigo Company plc Investors of Class Action Lawsuit

NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds investors who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE:PRGO) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

If you suffered a loss on your Perrigo investments, you have until January 16, 2026 to request lead plaintiff appointment. Follow the link below for more information:

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of February 27, 2023 through November 4, 2025, inclusive (“the Class Period”). The lawsuit alleges that Perrigo made materially false and/or misleading statements and/or failed to disclose to investors: (1) that the infant formula business acquired from Nestle suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; and (4) that, as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated.

On November 5, 2025, Perrigo released its third quarter 2025 financial results and lowered its full year guidance “due to soft OTC consumption & infant formula dynamics.” The Company also disclosed it was “initiating a strategic review of its infant formula business” including “reassessing the Company’s previously announced investment in this business of $240 million.” On this news, the price of Perrigo shares declined by $5.09 per share, or approximately 25.2%, from $20.19 per share on November 4, 2025 to close at $15.10 on November 5, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Perrigo securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[HOW CAN I PROTECT MY RIGHTS?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

Lauren Molinaro, Esq.

212-699-1171

https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Market Opportunity
FORM Logo
FORM Price(FORM)
$0.3681
$0.3681$0.3681
+1.71%
USD
FORM (FORM) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.